XL765 (BioDeep_00000771875)
代谢物信息卡片
化学式: C31H29N5O6S (599.1838454000001)
中文名称: N-[2-[(3,5-二甲氧基苯基)氨基]喹喔啉-3-基]-4-[(4-甲基-3-甲氧基苯基)羰基]氨基苯磺酰胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC3=NC4=CC=CC=C4N=C3NC5=CC(=CC(=C5)OC)OC)OC
InChI: InChI=1S/C31H29N5O6S/c1-19-9-10-20(15-28(19)42-4)31(37)33-21-11-13-25(14-12-21)43(38,39)36-30-29(34-26-7-5-6-8-27(26)35-30)32-22-16-23(40-2)18-24(17-22)41-3/h5-18H,1-4H3,(H,32,34)(H,33,37)(H,35,36)
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:71958
- PubChem: 49867926
- ChEMBL: CHEMBL3349370
- CAS: 1123889-87-1
- CAS: 1349796-36-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Janice M Mehnert, Gerald Edelman, Mark Stein, Heather Camisa, Joanne Lager, Jean-François Dedieu, Anne-Frédérique Ghuysen, Jyoti Sharma, Li Liu, Patricia M LoRusso. A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
Investigational new drugs.
2018 02; 36(1):36-44. doi:
10.1007/s10637-017-0467-7. [PMID: 28417284] - Farrukh T Awan, Lia Gore, Lei Gao, Jyoti Sharma, Joanne Lager, Luciano J Costa. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
British journal of haematology.
2016 Oct; 175(1):55-65. doi:
10.1111/bjh.14181. [PMID: 27293194] - Patrick Y Wen, Antonio Omuro, Manmeet S Ahluwalia, Hassan M Fathallah-Shaykh, Nimish Mohile, Joanne J Lager, A Douglas Laird, Jiali Tang, Jason Jiang, Coumaran Egile, Timothy F Cloughesy. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Neuro-oncology.
2015 Sep; 17(9):1275-83. doi:
10.1093/neuonc/nov083. [PMID: 26019185] - Kyriakos P Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W Tolcher, José Baselga, Weiliang Shi, Coumaran Egile, Rodrigo Ruiz-Soto, A Douglas Laird, Dale Miles, Patricia M Lorusso. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2014 May; 20(9):2445-56. doi:
10.1158/1078-0432.ccr-13-2403. [PMID: 24583798] - Congxin Dai, Bo Zhang, Xiaohai Liu, Sihai Ma, Yakun Yang, Yong Yao, Ming Feng, Xinjie Bao, Guilin Li, Janxin Wang, Kai Guo, Wenbin Ma, Bing Xing, Wei Lian, Jianqi Xiao, Feng Cai, Hongbin Zhang, Renzhi Wang. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Endocrinology.
2013 Mar; 154(3):1247-59. doi:
10.1210/en.2012-1908. [PMID: 23384836] - C Garcia-Echeverria, W R Sellers. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
Oncogene.
2008 Sep; 27(41):5511-26. doi:
10.1038/onc.2008.246. [PMID: 18794885]